ADXS - アドバクシス (Advaxis Inc.) アドバクシス

 ADXSのチャート


 ADXSの企業情報

symbol ADXS
会社名 Advaxis Inc (アドバクシス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アドバキシス(Advaxis Inc.)はリステリア・モノサイトゲネス(Lm)-リステリオリシン O(LLO)癌免疫療法の発見・開発・商業化に従事する臨床段階のバイオ技術会社である。これらの免疫療法は、抗原/アジュバント融合タンパク質を分泌する生きた弱毒化Lmバイオエンジニアリングを利用するプラットフォーム技術に基づいている。これらのLm-LLO株は、抗腫瘍T細胞免疫を刺激し、複数のアジュバントの等価物で免疫系を刺激・活性化するために、抗原提示細胞にアクセスして誘導すると同時に複数の機能を単一の免疫療法に統合し、同時にT細胞が腫瘍を排除することを可能にするために腫瘍微小環境における腫瘍保護を低下させる。Axalimogene filolisbacは、ヒトパピローマウイルス関連癌の治療用のリードLm-LLO免疫療法製品候補である。ADXS-PSAは、前立腺癌に関連する前立腺特異抗原(PSA)を標的とするLm-LLO免疫療法製品候補である。   アドバクシスは米国のバイオテクノロジ―企業。がんおよび感染症のための免疫療法の開発に従事。開発中の医薬品は、子宮頸がん、頭頸部がん、肛門がんの治療薬「ADXS-HPV」、前立腺がん向け「ADXS-PSA」、乳がん、胃がんや、ヒトにおける他のがんおよび犬の骨肉腫などのHER2過剰発現がんの治療薬「ADXS-cHER2」の開発を手掛ける。   
本社所在地 305 College Road East Princeton NJ 08540 USA
代表者氏名 David Sidransky デビッド・シドランスキー
代表者役職名 Independent chairman of the Board
電話番号 +1 732-545-1590
設立年月日 31929
市場名 NASDAQ National Market System
ipoyear ―年
従業員数
url www.advaxis.com
nasdaq_url https://www.nasdaq.com/symbol/adxs
adr_tso
EBITDA EBITDA(百万ドル) -74.67294
終値(lastsale) 0.792
時価総額(marketcap) 55040158.008
時価総額 時価総額(百万ドル) 58.15208
売上高 売上高(百万ドル) 6.69732
企業価値(EV) 企業価値(EV)(百万ドル) 18.71808
当期純利益 当期純利益(百万ドル) -71.17769
決算概要 決算概要 BRIEF: For the nine months ended 31 July 2018 Advaxis Inc. revenues decreased 52% to $4.9M. Net loss decreased 32% to $47.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative decrease of 79% to $3.6M (expense) Research and Development Expenses decrease of 17% to $36.1M (expense) Other decrease of 31% to $10.9M (expense).

 ADXSのテクニカル分析


 ADXSのニュース

   The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback  2020/11/25 12:35:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24) AbbVie Inc (NYSE: ABBV ) Affimed NV (NASDAQ: AFMD ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cellectis SA (NASDAQ: CLLS ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Generation Bio Co (NASDAQ: GBIO ) Inspire Medical Systems Inc (NYSE: INSP ) Kronos Bio Inc (NASDAQ: KRON ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) NeoGenomics, Inc. (NASDAQ: NEO ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Pulmonx Corp (NASDAQ: LUNG ) Relay Therapeutics Inc (NASDAQ: RLAY ) Sotera Health Co (NASDAQ: SHC ) (began trading on Nasdaq Friday following its IPO) Trinity Biotech plc (NASDAQ: TRIB ) Veracyte Inc (NASDAQ: VCYT ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 24) Advaxis, Inc. (NASDAQ: ADXS ) ( announced a public offering of common stock and warrants) Immunome Inc (NASDAQ: IMNM ) InMed Pharmaceuticals Inc (NASDAQ: INM ) Kiromic Biopharma Inc (NASDAQ: KRBP ) Maravai Lifesciences Holdings Inc (NASDAQ: MRVI ) debuted on Wall Street Friday) Qualigen …
   Cervical Cancer Treatment Market to Observe Exponential Growth by 2020-2027 | Biocon, Advaxis, Amgen, Genentech  2020/11/17 18:01:18 OpenPR
Cervical cancer is the uncontrollable growth of tumor in the cervix, the condition is recognized by symptoms such as, abnormal vaginal discharge, abnormal vaginal bleeding and pelvic pain. Some of the common methods of cervical cancer are chemotherapy radiation therapy,
   Cancer Immunotherapy Market With Top Key Players like F. Hoffmann-La Roche AG, Advaxis, Merck & Co., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, Novartis AG, Bayer AG, Immunomedics, Astrazeneca  2020/11/11 07:44:18 OpenPR
Cancer immunotherapy is a therapy that utilizes part of patients' immune system to fight against cancer. The therapy stimulates the person's own immune system to attack the cancer cells. There are different types of immunotherapy that includes monoclonal antibodies, immune
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Advaxis (NASDAQ:ADXS) Stock Price Up 10.9%  2020/10/21 17:37:11 US Banking News
Advaxis, Inc. (NASDAQ:ADXS) shares rose 10.9% during mid-day trading on Wednesday . The stock traded as high as $0.54 and last traded at $0.51. Approximately 15,064,634 shares traded hands during trading, an increase of 463% from the average daily volume of 2,673,818 shares. The stock had previously closed at $0.46. The firm has a market […]
   Cancer Immunotherapy Market With Top Key Players like F. Hoffmann-La Roche AG, Advaxis, Merck & Co., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer, Novartis AG, Bayer AG, Immunomedics, Astrazeneca  2020/11/11 07:44:18 OpenPR
Cancer immunotherapy is a therapy that utilizes part of patients' immune system to fight against cancer. The therapy stimulates the person's own immune system to attack the cancer cells. There are different types of immunotherapy that includes monoclonal antibodies, immune
   The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions  2020/11/08 17:47:42 Benzinga
Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of guard at the White House. The week witnessed a flurry of earnings from several smid-cap companies. Bluebird bio Inc. (NASDAQ: BLUE ) shares came under pressure after it announced a push back in the timeline for the regulatory filing for its gene therapy to treat sickle cell disease. Biogen Inc. (NASDAQ: BIIB ) was also in the news over an FDA roadblock regarding its Alzheimer's drug aducanumab. On the M&A front, Merck & Co. Inc. (NYSE: MRK ) announced a $2.75 billion deal to buy oncology-focused biopharma VelosBio Inc. Here are the key biotech events to watch out for in the unfolding week: Conferences American College of Rheumatology, or ACR, Convergence 2020: Nov. 5-9 Credit Suisse 29th Annual Virtual Healthcare Conference: Nov. 9-10 35th Annual Meeting of The Society for Immunotherapy of Cancer, or SITC: Nov. 9-14 American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov.
   Advaxis (NASDAQ:ADXS) Stock Price Up 10.9%  2020/10/21 17:37:11 US Banking News
Advaxis, Inc. (NASDAQ:ADXS) shares rose 10.9% during mid-day trading on Wednesday . The stock traded as high as $0.54 and last traded at $0.51. Approximately 15,064,634 shares traded hands during trading, an increase of 463% from the average daily volume of 2,673,818 shares. The stock had previously closed at $0.46. The firm has a market […]
   Cancer Vaccines Market SWOT Analysis by Key Players: Advaxis, Advantagene, Agenus  2020/10/13 08:44:26 OpenPR
COVID-19 Outbreak-Global Cancer Vaccines Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The
   Cancer Immunotherapy Market Year: 2020-2027 Forecasts and its Details Analysis by Advaxis, Merck & Co. Inc., Immunomedics Inc., Bayer AG, Pfizer Inc.  2020/10/12 12:57:34 OpenPR
A report by The Insight Partner's on the Cancer Immunotherapy Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
   Advaxis (NASDAQ:ADXS) Stock Price Up 10.9%  2020/10/21 17:37:11 US Banking News
Advaxis, Inc. (NASDAQ:ADXS) shares rose 10.9% during mid-day trading on Wednesday . The stock traded as high as $0.54 and last traded at $0.51. Approximately 15,064,634 shares traded hands during trading, an increase of 463% from the average daily volume of 2,673,818 shares. The stock had previously closed at $0.46. The firm has a market […]
   Cancer Vaccines Market SWOT Analysis by Key Players: Advaxis, Advantagene, Agenus  2020/10/13 08:44:26 OpenPR
COVID-19 Outbreak-Global Cancer Vaccines Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The
   Cancer Immunotherapy Market Year: 2020-2027 Forecasts and its Details Analysis by Advaxis, Merck & Co. Inc., Immunomedics Inc., Bayer AG, Pfizer Inc.  2020/10/12 12:57:34 OpenPR
A report by The Insight Partner's on the Cancer Immunotherapy Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in the
   Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others  2020/09/08 15:45:00 PR Newswire
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- The "Cancer Vaccines Market by Technology, Type, Indication and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cancer vaccines market was valued at $4,188…
   Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update  2019/12/20 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2019 and provides a business update. Fiscal Year 2019 and Recent Key Accomplishments Completed enrollment in the first and second dose levels in Part A of the ongoing Phase 1/2 trial evaluating ADXS-503, the Company’s ADXS-HOT drug candidate in

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アドバクシス ADXS Advaxis Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)